Tag Archives: Sugen

Sugen Inc. has sidestepped a post grant opposition to its lung cancer drug Xalkori (crizotinib) after what seems like a settlement with opponent Fresenius Kabi Oncology Ltd. Also engaged in the development and manufacture of cancer drugs, Fresenius Kabi filed two post grant oppositions to Sugen’s Xalkori patent in 2012 on multiple grounds. On 29th April, 2015, the Controller issued a decision allowing Fresenius Kabi’s request for withdrawal of their oppositions. It is unclear how and why this withdrawal came about, with…

The Sunitinib Saga continues: Third time’s the charm?

by Madhulika Vishwanathan June 8, 2013

10 Comments

The IPAB has set aside the revocation of Sunitinib patent due to procedural lapses again!!(IPAB order can be accessed here). As Sunny Deol would drawl “tariq pe tariq, tariq pe tariq…” (movie buffs you know what I’m talking about).Well Justice Prabha Sridevan also expressed a similar sentiment albeit in different way and stated that the Sunitinib litigation has been delayed endlessly owing to procedural lapses in the IPO and this is unfair to both the patentee and the challenger and also…

Others

Spicy IP Tidbit: Indian patent office puts an end to Sunitinib saga

by Madhulika Vishwanathan February 15, 2013

4 Comments

Image from here Pfizer/Sugen was granted a patent on anti-cancer drug Sunitib (Patent number: 209251) on Oct 5, 2007.Nearly 5 years later in a post grant opposition initiated by Cipla, this patent was revoked by the patent office on the grounds of obviousness. An excellent analysis of this decision is covered here. As reported by Prashant, in a rather surprising turn of events, patentees (Pfizer/Sugen) filed a writ petition before Delhi High court requesting that the revocation decision…

Drug Regulation

Breaking news: Cipla succeeds in revoking Pfizer / Sugen’s patent on Sunitinib

by Rajiv Kr. Choudhry October 3, 2012

2 Comments

The Patent Office in a recent post grant opposition proceeding brought by Cipla against Pfizer / Sugen’s patent on the drug Sunitinib, revoked Indian patent IN209251. The drug Sunitinib is used to treat diseases caused by abnormal protein kinase activity. Interestingly the patent was revoked primarily on the ground that it lacked an inventive step (Section 2(1)(j)). Pfizer / Sugen had earlier succeeded in defending a compulsory license (CL) proceeding earlier for the same patent. The CL proceeding was withdrawn by…

Kunal Bindra { Would be very interesting to see how 'ordinarily' is interpreted. Section 30 anyway allows PPL and Novex to function as de facto Copyright Societies/CMOs. }
Adyasha Samal { That's right, it is an ad-interim injunction. I realize that's not very clear from the post (will add an edit), but my point here is not that granting... }
Jagdish Sagar { I have noticed this interesting article a little late. Three comments: (1) there is absolutely no discussion or reference to section 3 of the Copyright Act which defines... }
Anon { "It is important to note that S&S Canada had not filed a written statement, but the interim injunction was granted nonetheless." Please note that the language of the... }
V.P { Mr. Khadher, I am currently reading a copy of this book, and have read your review and comments with interest. I think you have made some valid points,... }

De-Coding Indian Intellectual Property Law

Tag Archives: Sugen

Opposition to Sugen’s Lung Cancer Drug Patent Withdrawn

The Sunitinib Saga continues: Third time’s the charm?

Spicy IP Tidbit: Indian patent office puts an end to Sunitinib saga

Breaking news: Cipla succeeds in revoking Pfizer / Sugen’s patent on Sunitinib